About Company
Founded in 2018 and headquartered in San Francisco, California, 89bio is dedicated to addressing significant unmet medical needs through its advanced therapeutic candidates. The company’s lead product candidate, pegozafermin, is a glycoPEGylated fibroblast growth factor 21 (FGF21) analog designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
Key Areas of Focus
- Liver Diseases: Developing therapies specifically aimed at conditions like MASH, which affects liver health and function.
- Cardiometabolic Disorders: Targeting diseases related to metabolism and cardiovascular health, with a focus on reducing triglyceride levels and improving overall metabolic profiles.
- Clinical Trials: Currently conducting pivotal Phase 3 trials for pegozafermin, with topline data expected in the coming years.
89bio emphasizes a strong commitment to scientific innovation and has built a leadership team with extensive experience in drug development and commercialization.